Cognition Therapeutics Inc CGTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.93
- Day Range
- $1.87–1.97
- 52-Week Range
- $0.90–3.49
- Bid/Ask
- $1.75 / $1.95
- Market Cap
- $76.05 Mil
- Volume/Avg
- 55,056 / 205,517
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 25
- Website
- https://www.cogrx.com
Comparables
Valuation
|
Metric
|
CGTX
|
MORF
|
PLRX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.63 | 1.98 | 1.50 |
Price/Sales | — | 2,253.05 | 441.50 |
Price/Cash Flow | — | — | — |
Price/Earnings
CGTX
MORF
PLRX
Financial Strength
|
Metric
|
CGTX
|
MORF
|
PLRX
|
|---|---|---|---|
Quick Ratio | 3.07 | 28.43 | 17.43 |
Current Ratio | 3.37 | 28.94 | 17.72 |
Interest Coverage | −954.11 | — | −145.34 |
Quick Ratio
CGTX
MORF
PLRX
Profitability
|
Metric
|
CGTX
|
MORF
|
PLRX
|
|---|---|---|---|
Return on Assets (Normalized) | −50.08% | −18.85% | −22.68% |
Return on Equity (Normalized) | −65.42% | −19.43% | −24.50% |
Return on Invested Capital (Normalized) | −63.15% | −23.26% | −28.46% |
Return on Assets
CGTX
MORF
PLRX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Tshzcfhlm | Tnv | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vhdwtxxy | Xqwhxkl | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qqvpcprtb | Mmnbl | $97.8 Bil | |
MRNA
| Moderna Inc | Hjgtnxq | Gjb | $41.3 Bil | |
ARGX
| argenx SE ADR | Wpcwjcwf | Bdwwb | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Pphlcyjc | Cdxf | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ssgfhmk | Rskprsz | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Swxwdskff | Lnzhtt | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gvwrknpjwb | Gmzvyk | $12.5 Bil | |
INCY
| Incyte Corp | Rygsvwr | Tswyzn | $11.6 Bil |